Post transplant lymphoproliferative disease: detection of tumor by Tc99m sestaMIBI and treatment with rituximab
نویسندگان
چکیده
منابع مشابه
Rituximab for post-transplant lymphoproliferative disease
Post-transplant lymphoproliferative disease (PTLD) describes a heterogenous group of lymphoproliferative diseases, occurring as a result of uncontrolled B cell proliferation in the context of post-transplant immunosuppression. The incidence depends on the type of transplant and immunosuppression used; the median time to onset is shorter for recipients of stem cell transplants (2 months) than th...
متن کاملRituximab for post-transplant lymphoproliferative disease _PTLD.pub
Rituximab is a monocloncal antibody that binds specifically to CD20, an antigen expressed on the surface of mature and immature B lymphocytes. The binding of rituximab to CD20 results in cell lysis via the recruitment of immune effector functions; it has also been demonstrated to induce cell death via apoptosis. Rituximab (Mabthera®) is licensed in the UK for the treatment of Non-Hodgkin’s lymp...
متن کاملRituximab Is Indispensable for Pediatric Heart Transplant Recipients Developing Post transplant Lymphoproliferative Disorders
Abstract Rituximab, an anti-CD20 agent, has been suggested as an effective strategy to deal with post transplant lymphoproliferative disorders (PTLD). In the current study, we aim to evaluate the efficacy of rituximab therapy in heart transplant population developing PTLD. A comprehensive search of the literature was performed to gather the available data on lymphoproliferative disorders oc...
متن کاملEBV-reactivation and post-transplant lymphoproliferative disorder treated with rituximab.
We read the recent paper on profile of EBV-associated infectious mononucleosis (IM) by Balasubramanian, et al. [1] with interest. They concluded that EBV associated IM is more common in preschool children. Here we highlight another dreaded complication due to reactivation of EBV post-allogeneic stem cell transplant (SCT) leading to post-transplant lymphoproliferative disorder (PTLD). Mortality ...
متن کاملSuccessful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a complication of hematopoietic stem cell transplantation (HSCT). Standard initial treatment of patients with EBV-PTLD includes administration of rituximab or dose reduction of a calcineurin inhibitor. We report successful chemotherapeutic treatment of rituximab-resistant EBV-PTLD after HSCT in a pati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Bone Marrow Transplantation
سال: 2004
ISSN: 0268-3369,1476-5365
DOI: 10.1038/sj.bmt.1704794